This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cyberonics: Growth in Medical Equipment

CHARLOTTE, N.C. ( TheStreet) -- I like growth stocks and so should you. The object of managing your own portfolio is to whittle down the 12,000 stocks you might invest in and find the dozen you need for your portfolio that fits all of your criteria and has the best chance to beat the market.

I think the medical appliance and equipment company Cyberonics (CYBX - Get Report) is that kind of stock and I'll walk you through the reasons why.

First I like to see price momentum. If the market isn't responding to a stock, why should you? In the past month the stock has been up almost 8% as you can see in this hourly trading chart provided by Barchart:

The recent momentum is there but how has the stock done against the rest of the market? During the past six months, the market as measured by the Value Line Index is up about 3% but CYBX is up 23%:

Cyberonics, a neuromodulation company, engages in the design, development, sale, and marketing of implantable medical devices that provide vagus nerve stimulation therapy for the treatment of refractory epilepsy and treatment-resistant depression. Its proprietary VNS therapy system consists of a generator to provide the stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; associated equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters particular to the patient; instruction manuals; and magnets to suspend or induce stimulation manually.

The company sells its products through a direct sales force in the U.S., as well as through a combination of direct sales representatives and independent distributors internationally. Cyberonics was founded in 1987 and is headquartered in Houston (according to a Yahoo Finance profile).

Factors to consider:

Barchart technical indicators:
  • 100% Barchart technical buy signal
  • Trend Spotter buy signal
  • Above its 20-, 50- and 100-day moving averages
  • 7 new highs and up 7.78% in the last 20 trading sessions
  • Relative Strength Index 68.78
  • Barchart computes a technical support level at 36.44
  • Recently traded at 41.62 with a 50 day moving average of 38.31
  • Fundamental factors:
  • Wall Street has already noticed this stock and six brokerage firms have assigned nine analysts to make a recommendation
  • Analysts project revenue will increase by 11.40% this year and another 13% next year
  • Earnings are estimated to increase by 16.7% this year, an additional 20.1% next year and continue at an annual rate of 26.25% over the next five years
  • These estimates resulted in five strong buy, two buy, two hold and no underperform or sell recommendations to clients
  • If the numbers hold investors should see an 11%-to-15% annual rate of return for at least five years
  • The company has a B+ financial strength rating
  • The P/E of 29.56 is higher than the market P/E of 14.40 and the stock pays no dividend
  • Medical ETFs are beginning to accumulate shares
  • The company is expanding sales in Europe and Japan
  • The research and development budget is being spent in new product development in rechargeable batteries, seizure detection and sleep apnea devices
  • Investor Interest:
  • Some of the firms with recent upgrades were Kaufman Brothers and Zachs.
  • Stock strategist Charles Payne spoke positively about the company.
  • The readers of TheStreet give the stock an A- rating.
  • Competition:

    The market is the best scorecard and I always like to invest in sector leaders by charting how the stock does against the rest of the competition. During the past year Medtronics (MDT - Get Report) was down 4%, as was Covidien (COV). Baxter International (BAX - Get Report) was down even further, by 13%, while Cyberonics soared 53%:

    1 of 2

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Options Profits

    Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

    Product Features:
    • Actionable options commentary and news
    • Real-time trading community
    SYM TRADE IT LAST %CHG
    COV $106.71 -1.26%
    BAX $40.08 0.00%
    CYBX $61.40 0.00%
    MDT $78.39 0.00%
    AAPL $121.30 0.00%

    Markets

    Chart of I:DJI
    DOW 17,689.86 -56.12 -0.32%
    S&P 500 2,103.84 -4.79 -0.23%
    NASDAQ 5,128.2810 -0.5040 -0.01%

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs